drugset
drugset / Trial / NCT03393936

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma

NCT03393936 ↗

Phase 1/2 Terminated 66 enrolled Shanghai PerHum Therapeutics Co., Ltd. Shanghai Public Health Clinical Center · collab
Non-randomizedFactorialOpen-labelTreatment

Summary

This is a two arm, open-label, dose escalation and dose expansion clinical study to evaluate the safety and efficacy of infusion of autologous CCT301-38 or CCT 301-59 T cells in adult subjects with relapsed and refractory stage IV metastatic renal cell carcinoma.Subjects with ROR2 positive biopsy will receive CCT301-59. Subjects with AXL positive biopsy that are ROR2 negative will receive CCT301-38.

Timeline

Start
2018-03-26
Primary completion
2022-06-30
Completion
2023-06-30

Outcome

Outcome not reported

Stopped (Business): “Adjustment of study strategy”

Drugs

EvaluationDrugModalityDoseRoute
Subject CCT301-38 Cell therapy 100000 cells/kg Intravenous
Subject CCT301-38 Cell therapy 1e+06 cells/kg Intravenous
Subject CCT301-38 Cell therapy 1e+07 cells/kg Intravenous
Subject CCT301-59 Cell therapy 100000 cells/kg Intravenous
Subject CCT301-59 Cell therapy 1e+06 cells/kg Intravenous
Subject CCT301-59 Cell therapy 1e+07 cells/kg Intravenous

Indications

renal cell carcinoma